Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood vessel drug ease Raynaud's in scleroderma?

NCT ID NCT02260557

Symptom relief Sponsor: Actelion Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested whether selexipag, a drug that opens blood vessels, can reduce the number of Raynaud's attacks in adults with systemic sclerosis. 74 participants took either selexipag or a placebo twice daily. The main goal was to see if the drug lowered weekly attack frequency.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
selexipag
What this could lead to
If it works, this could point toward a new treatment to reduce the number of Raynaud's attacks in people with systemic sclerosis.
What could go wrong
This is an early Phase 2 trial with only 74 people, so results may not be conclusive. The drug may not reduce attacks more than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

74 people

The number who actually took part.

Started

Oct 2014

Finished

Jun 2015

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key inclusion criteria: * Signed informed consent prior to any study-mandated procedure. * Male and female subjects aged 18 years and above with a history of recurrent multiple weekly RP attacks secondary to SSc. * Women of childbearing potential must agree to use a reliable method of birth control. Key exclusion criteria: * Known moderate or severe hepatic impairment (i.e. Child-Pugh C). * Known hypersensitivity to selexipag or drugs of the same class, or any of their excipients. * Subjects who have received prostacyclin (epoprostenol) or prostacyclin analogs (i.e., treprostenol, iloprost, beraprost) within 3 months prior to the screening visit. * Subjects who have received a Phosphodiesterase type 5 (PDE-5) inhibitor within 1 week prior to the screening visit. * Any dose change or initiation of any of the following drugs within 1 month prior to the screening visit: Calcium channel blockers, Nitrates or nitric oxide donors, ERA's, Alpha-blockers, Antithrombotic agents, NSAIDs (occasional use allowed), Angiotensin Converting Enzyme (ACE) inhibitors, Beta-blockers, Clonidine, Systemic corticosteroids, Fluoxetine. * Severe renal insufficiency (at randomization). * Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Raynaud's phenomenon secondary to systemic sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Raynaud disease systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Raynaud's phenomenon secondary to systemic sclerosis

Contacts and locations

Locations

  • Investigator Site

    Grenoble, 38043, France

  • Investigator Site

    Lille, 59037, France

  • Investigator Site

    Nantes, 44093, France

  • Investigator Site

    Paris, 75679, France

  • Investigator Site

    Strasbourg, 67200, France

  • Investigator Site

    Bad Nauheim, 61231, Germany

  • Investigator Site

    Berlin, 10117, Germany

  • Investigator Site

    Cologne, 50937, Germany

  • Investigator Site

    Erlangen, 91054, Germany

  • Investigator Site

    Magdeburg, 39120, Germany

  • Investigator Site

    Mainz, 55131, Germany

  • Investigator Site

    Bath, BA11RL, United Kingdom

  • Investigator Site

    Leeds, LS74SA, United Kingdom

  • Investigator Site

    Liverpool, L97AL, United Kingdom

  • Investigator Site

    London, NW32QG, United Kingdom

  • Investigator Site

    Salford, M55AP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.